Loading...
XSHG603590
Market cap478mUSD
Jan 10, Last price  
22.08CNY
1D
-0.49%
1Q
-4.02%
IPO
-59.04%
Name

Beijing Konruns Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:603590 chart
P/E
22.93
P/S
3.75
EPS
0.96
Div Yield, %
1.01%
Shrs. gr., 5y
3.29%
Rev. gr., 5y
-2.08%
Revenues
920m
+6.15%
598,384,502544,488,429436,147,628346,225,368590,580,0851,022,164,2651,065,924,550808,643,947809,782,217866,725,922920,011,779
Net income
150m
+48.24%
118,436,972175,896,818195,250,559191,653,276478,817,120263,929,840266,080,142183,358,787147,985,907101,490,338150,450,744
CFO
199m
+66.56%
163,718,800130,978,200191,804,479148,260,413270,486,916263,108,138262,004,45258,405,51570,912,504119,690,343199,353,548
Dividend
Jul 04, 20240.3 CNY/sh
Earnings
May 16, 2025

Profile

Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research, production, and sale of various drugs in China. The company offers Su Ling product in the hemagglutinin preparation market used to reduce bleeding during surgery and control postoperative surgery. It also engages in the development of drug candidates, including CX1026, CX1003, and KC1036. The company was founded in 2003 and is headquartered in Beijing, China.
URL
http://www.konruns.cn/
IPO date
Aug 27, 2018
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
920,012
6.15%
866,726
7.03%
Cost of revenue
708,130
669,234
Unusual Expense (Income)
NOPBT
211,882
197,492
NOPBT Margin
23.03%
22.79%
Operating Taxes
(64,839)
16,422
Tax Rate
8.32%
NOPAT
276,721
181,070
Net income
150,451
48.24%
101,490
-31.42%
Dividends
(34,949)
(46,947)
Dividend yield
0.59%
1.20%
Proceeds from repurchase of equity
42,379
BB yield
-0.71%
Debt
Debt current
100,877
8,712
Long-term debt
47,734
7,416
Deferred revenue
23,486
28,980
Other long-term liabilities
1
1
Net debt
(890,439)
(1,003,065)
Cash flow
Cash from operating activities
199,354
119,690
CAPEX
(100,913)
Cash from investing activities
(447,715)
Cash from financing activities
143,621
FCF
145,239
112,812
Balance
Cash
626,609
625,619
Long term investments
412,442
393,574
Excess cash
993,050
975,857
Stockholders' equity
2,511,462
2,338,108
Invested Capital
2,537,477
2,216,096
ROIC
11.64%
8.80%
ROCE
5.95%
6.13%
EV
Common stock shares outstanding
156,720
156,491
Price
38.08
52.69%
24.94
-23.24%
Market cap
5,967,880
52.91%
3,902,895
-23.70%
EV
5,379,878
3,164,048
EBITDA
254,822
236,208
EV/EBITDA
21.11
13.40
Interest
2,394
864
Interest/NOPBT
1.13%
0.44%